Tivozanib mediated inhibition of c-Kit/SCF signaling on Tregs and MDSCs and reversal of tumor induced immune suppression correlates with survival of HCC patients

The immune modulatory effect of tivozanib, a tyrosine kinase inhibitor, and the underlying immune mechanisms impacting survival of HCC patients have not been investigated. Pre-clinical studies have shown that tivozanib reduces Tregs and MDSCs accumulation through inhibition of c-Kit/SCF axis. We rat...

Descripción completa

Detalles Bibliográficos
Autores principales: Kalathil, Suresh Gopi, Wang, Katy, Hutson, Alan, Iyer, Renuka, Thanavala, Yasmin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7553535/
https://www.ncbi.nlm.nih.gov/pubmed/33101775
http://dx.doi.org/10.1080/2162402X.2020.1824863

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7553535/
https://www.ncbi.nlm.nih.gov/pubmed/33101775
http://dx.doi.org/10.1080/2162402X.2020.1824863

Ejemplares similares